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Abstract
Background: Single-domain antibody fragments possess structural features, such as a small dimension, an elevated
stability, and the singularity of recognizing epitopes non-accessible for conventional antibodies that make them
interesting for several research and biotechnological applications.
Results: The discovery of the single-domain antibody’s potentials has stimulated their use in an increasing variety
of fields. The rapid accumulation of articles describing new applications and further developments of established
approaches has made it, therefore, necessary to update the previous reviews with a new and more complete
summary of the topic.
Conclusions: Beside the necessary task of updating, this work analyses in detail some applicative aspects of the
single-domain antibodies that have been overseen in the past, such as their efficacy in affinity chromatography, as
co-crystallization chaperones, protein aggregation controllers, enzyme activity tuners, and the specificities of the
unconventional single-domain fragments.
Introduction
Conventional poly-and monoclonal antibodies are still
indispensable reagents in basic research and diagnostics.
Nevertheless, both of them have some shortcomings-
most of all the batch-to-batch variability of the polyclo-
nal antibodies and the elevated costs and long time
necessary for the production of the monoclonal ones.
Furthermore, their dimension is detrimental for some
diagnostic and therapeutic applications since it limits
the efficient penetration into solid tumors and the pas-
sage through the blood-brain barrier. All these reasons
urged the development of strategies aimed at the pro-
duction of alternative scaffolds [1] and recombinant
antibodies of smaller dimensions that could be easily
selected, produced, and manipulated using standard
molecular biology techniques.
Although a vast number of recombinant antibody
structures has been proposed [2], the single chain
(scFv) and the single domain (VHH, VH, and NAR V)
formats are the most widespread for both research and
industrial applications [2-4]. Recombinant antibodies
seem particularly promising as immunoconjugates [5,6]
and for activating the biosensor chip surfaces for
detecting specific antigens [7]. Specifically, VHHs suc-
ceed in targeting brain epitopes by transmigrating
through the blood-brain barrier [8,9], can be used for
tuning and detecting the activity of cell proteins in
vivo [10-13], provide better diffusion in fixed cells in
comparison to conventional antibodies [14], and can
simplify the generation of anti-idiotypic antibodies sui-
table for vaccination [15].
The success of the technology makes it impossible to
r e v i e wt h ee n t i r el i t e r a t u r ec o n c e r n i n gt h ed i f f e r e n t
classes of antibody fragments and their applications in
biology. The modes of application of VHHs, even
though recently reviewed [4,16], constantly increase in
numbers with the publication of new reports describ-
ing innovative uses. Therefore, this paper will on the
one side integrate information concerning the estab-
lished biotechnological utility of single-domain antibo-
dies with the most recent data. On the other side, it
will overview the potentials of the different classes of
single-domain antibodies that developed massively in
the last two years, such as immunoaffinity, assisted
crystallography, protein aggregation and activity tun-
ing, and toxin inactivation, for which a systematic
update is now necessary.
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Camelidae single-chain antibodies and their recombi-
nant VHH domains have ceased to be an exotic group
with a merely theoretical interest and have become an
established tool in biology and biotechnology. The num-
ber of publications that increases year in and year out
testifies that an ever larger number of research groups
work successfully with these molecules in different
fields. Although not equally widespread, also the single
chain antibodies of shark origin (IgNAR) have seen an
increasing interest as a source of single-domain antibo-
dies. In contrast, the scientific community is probably
less aware of the qualities of other single-domain anti-
bodies, the existence of which was for long time consid-
ered a simple anomaly (Figure 1).
VHH stability has been attributed to the mutation of
the hydrophobic residues responsible for the interaction
between VL and VH domains [17]. However, there are
single-domains, such as the human VH domain HEL4,
that conserve conventional VH hallmarks but are stable
even in the absence of the pairing VL partner. HEL4
crystal structure suggests that the reason of its stability
is due to an interaction by which the CDR1 partially
masks the hydrophobic residues otherwise exposed on
the framework region [18]. This structural arrangement
resembles the stabilizing role of CDR3 residues observed
in some VHHs, resulting in a loop partially bending
over the framework [19] and indicates that single-
domain antibodies can display different conformational
patterns to prevent the exposure of potentially destabi-
lizing amino acids. Although useful, the necessity to
renounce the loop flexibility that contributes to the
framework stability constrains the theoretical variability
of the paratope in terms of shape and residues. In this
sense, a VH domain stabilized by the sole replacement
of the hydrophobic residues involved in the VL interac-
tion has been proposed since it would preserve the max-
imal structural adaptability of the CDR3 and offer an
ideal scaffold for generating libraries with loops hyper-
mutated with respect to both length and residue combi-
nation [17,20,21]. At the same time, these libraries
derived from human VHs would represent a source for
selecting binders with no immunogenic response and,
therefore, of great therapeutic interest.
For this purpose, it is relevant that individual VHs not
only have structural features similar to those of the
VHHs in terms of thermal stability and refolding effi-
ciency [22-24], but also that they are perfectly functional
in terms of antigen-binding characteristics, as initially
reported by Ward et al. [25]. The mouse VH domains
isolated by panning against lysozyme had affinity in the
20 nM range for their antigen and the same binding
affinity was calculated for other VH single-domain anti-
bodies isolated successively from a semi-synthetic library
[26]. Another single-domain antibody (clone V86) was
successfully used in several immunotechniques [27] and
its nature as a structurally independent domain was
confirmed by the observation that its specificity and affi-
nity for the antigen were almost completely lost when it
was coupled with a VL domain for reconstituting a scFv.
Single-domains with VH signature were isolated also
after panning of Camelidae libraries designed for sam-
pling only VHHs and their presence was considered as
the consequence of material contaminations during the
amplification steps of the single-domain DNA [28,29].
However, these VHs were functional and stable, indicat-
ing that they possessed structural features of indepen-
dent single-domain antibodies.
Finally, specific classes of VH domains have been
identified recently both in llama and mouse for which
the presence of the light chains is entirely optional since
they can either form conventional or equally functional
but single-domain antibodies [30,31]. The stability and
functionality of independent VHs is maintained also
when they are expressed as intrabodies [32,33].
The identification of stable VH domains has been
recognized as a potential opportunity to widen the over-
all pool of functional single-domain antibodies. From
this perspective, the protocol used for single-domain
library preparation has been modified for obtaining
mixed libraries containing the whole repertoire of both
VH and VHH domains. Stable and antigen-specific VH
domains were isolated by panning from these libraries
[34,35].
In contrast to VHs, only few independent VL domains
have been reported as maintaining the binding capacity
Conventional IgG Camelid IgG1  and   IgG2,3 IgNAR
Variable domains
V domain aa sequence 37 44 45 47
V   G L F/W
37 44 45 47
F   E R R/L/G
VH VHH
Figure 1 Representation of the single-domain antibody specific
features. Single-domain antibodies can derive from different
immunoglobulines. Camelid VHs and VHHs differ for four hallmark
amino acid residues that are crucial for preserving the V domain
stability when it is expressed paired to the VL domain or alone,
respectively.
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result from the in vitro cleavage of functional IgG frag-
ments, as in the case of the VL binder specific for the
streptococcal protein L [36] and of the VL-barnase
immunotoxin that accumulates soluble and functional in
E. coli cytoplasm [37].
Targeting bacteria and phages
Antibodies directed against pathogenic bacterial-specific
surface antigens enable to identify them in, and remove
them from, biological samples. The advantage of using
fragment antibodies lies in the fact that they lack the Fc
domain, an IgG conserved region recognized by related
proteins expressed by bacteria belonging to different
species. Consequently, conventional antibodies are not
suitable for specifically identifying a bacterial sub-group
inside a complex population, whereas single-domain
antibodies constitute a reliable tool for these diagnostic
applications. For instance, single-domain isolated from a
VH library [20] and directed towards the staphylococcal
Protein A has been used in diagnostic applications
based on both nanoparticles [38] and nanoaggregate-
embedded beads [39].
Antibodies can be used for preventing in vivo the
attachment of pathogenic bacteria to the target cells by
competing with them for the host cell receptors [40,41].
The main limitation of such a strategy is that it is diffi-
cult to provide constantly the necessary amount of anti-
body because of the titer dilution and molecule
clearance. The environment colonization with microbial
cell factories that ensure the production and secretion
of the competitor antibodies in situ represents a possibi-
lity to overcome this drawback, but IgG are not suitable
for this application, in the way that antibody fragments
are. Recombinant antibodies in scFv format raised
against the streptococcal cell surface antigenI/II and
transformed into lactobacilli were therefore used to
infect the oral cavity of model rats to inhibit Streptococ-
cus mutans, the agent responsible for dental caries. The
method succeeded in decreasing the development of
dental caries [42] and resulted more effective when anti-
body production was induced by a constitutive promoter
[41]. Nevertheless, VHHs were successively preferred to
scFvs because of their superior structural robustness
and demonstrated their effectiveness in controlling the
damage [43]. Orally administrated, transformed lactoba-
cilli were also successfully used for delivering anti-TNF
nanobodies to the colon at a concentration sufficient to
significantly reduce chronic colitis [44].
The small dimensions of VHHs allow also their fusion
to relatively large tags without negative effects in terms
of recombinant yields. Therefore, their fusion to glucose
oxidase for inducing the production of active forms of
oxygen with microbicidal effect in the oral cavity has
been proposed. This approach may offer a synergistic
effect due to the contribution of the direct competition
plus the antimicrobial enzymatic activity, but its effec-
tiveness remains uncertain in vivo [43,45].
Mutagenesis is another tool that can be exploited to
improve the in vivo reliability of antibacterial VHHs by
selecting variants with superior features for a critical
condition. A set of anti-E. coli F4 fimbriae antibodies
was isolated and the most promising clone was further
characterized. Even though very effective in vitro, it pro-
tected poorly the piglets from intestinal infection since
it was rapidly degraded [40]. Therefore, its proteolytical
stability was increased by mutagenesis for obtaining a
significantly more effective binder suitable for oral treat-
ment [46].
The control of the pathogenic bacterial infection can
be also addressed by reducing the bacterial resistance to
antibiotics. Microorganisms can survive in the presence
of inhibitors since they produce enzymes that metabo-
lize the antibiotics. This is the case of the beta-lacta-
mase, a secreted enzyme that hydrolyzes ampicillin-like
antibiotics. VHHs with beta-lactamase inhibitory effect
have been isolated [47] demonstrating the feasibility of
selecting single-domain antibodies that could silence
this resistance strategy, although no biotechnological
application has followed so far.
Unique features of the single-domain antibodies can
be illustrated by a further example. The addition of
recombinant VHH raised against a phage tail protein
involved in the host recognition prevented the infection
of Lactococcus lactis cultures by the p2 bacteriophage
[48,49]. Subsequently, the lactobacilli have been engi-
neered to produce directly phage-neutralizing VHHs at
a rate sufficient for protecting themselves from infec-
tions [50]. This method represents an interesting
approach for vaccinating microorganisms of biotechno-
logical interest with the scope of protecting them from
harmful aggressions of biotic and abiotic origin.
Single-domain antibodies against fungi and protozoans
The potentials of single-domain antibodies have been
only scarcely applied to fungi and protozoans. Neverthe-
less, those few projects have significantly contributed to
the understanding of some general antibody structural
features. It is the case of the antibodies raised against a
cell wall protein of Malassezia furfur,af u n g u si m p l i -
cated in dandruff. Since the selected VHH antibodies
should be potentially included in a shampoo formula-
tion, they had to resist to the harsh chemical conditions
brought about by elevated concentrations of anionic and
nonionic surfactants. Therefore, the panning washing
conditions were adapted to represent the high-detergent
content of shampoos [51]. This approach enabled the
recovery of VHHs with specifically increased stability
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of arginine at position 44 for improving this
characteristic.
IgNARs, the single-chain antibodies of shark origin,
have been used for identifying variable domains of the
malarial Apical Membrane Antigen 1 of Plasmodium
falciparum [52]. In sharks, IgNARs represent the anti-
body isotope responsible for antigen-driven immune
response and the generation of high affinity antibodies
as the consequence of rapid somatic hyper-mutation.
Therefore, the authors simulated the natural mutational
process by means of error prone PCR using conditions
that introduced a single mutation in the whole sequence
of the binder previously recovered by conventional pan-
ning. This approach allowed for the identification of
more affine variants that differed from the original NAR
V single-domain by having a less rigid structure, a fea-
ture that determined a betteri n d u c e df i tf o rt h ea n t i -
body-antigen complex and explained a slower
dissociation rate of the mutants. Co-crystallization
results indicated that the antibody’s CDR3 loops pene-
trated deeply into hydrophobic clefts on the antigen sur-
face and allowed for the identification of conserved
residues that could be targeted preferentially in order to
develop polymorphism-independent binders [53].
Single-domain antibodies can apparently also recog-
nize effectively epitopes of parasite glycoproteins both in
diagnostic settings and in vivo.I ti st h ec a s eo faV H H
that binds the Ts14 protein of Taenia solium with sub-
nanomolar affinity [54] and of other VHHs specific for
oligomannose residues of the variant surface glycopro-
tein from Tripanosoma b. rhodiense [55-57]. Pan-reac-
tive VHHs against Tripanosoma spp. were successively
isolated for developing a rapid flow-cytometric diagnos-
tic system for quantitative assess of the pathogen con-
centration in blood samples [57,58].
Strategies for virus detection and neutralization
Also in the case of viruses, recombinant antibodies have
been conceived as an inexpensive alternative to IgGs for
masking the virion proteins involved in the host recep-
tor binding and thus impairing the subsequent infection
in vivo [59]. Single-domain antibodies possess a large
protruding loop corresponding to the CDR3 and this
structural feature represents an advantage over conven-
tional antibodies in reaching the typically cryptic viral
epitopes responsible for host recognition, similarly to
what has been observed in the case of VHH competitive
inhibition of the enzymatic catalytic site [60]. On the
other hand, each virion usually contains tens of such
epitope copies. Although it is true that conventional
IgGs have no direct access to such hidden epitopes,
their large dimension can increase virus neutralization
by steric hindrance. To overcome the dimension
limitation of VHHs and improve their neutralizing capa-
city in vitro and in vivo, their mass was increased by
conjugation with immunoglobulins or inducing their N-
glycosylation by providing suitable residues and succes-
sive expression in yeast [61-63]. The approach of defin-
ing the residues for N-glycosylation by mutagenesis
should avoid specificity and affinity loss for the antigen
due to paratope modification and reduced epitope
accessibility. Nevertheless, the effectiveness of N-glyco-
sylation for in vivo applications is still to be demon-
strated because the large mannosylated carbohydrates
synthetized by yeast are actively bound by liver recep-
tors leading to fast VHH clearance.
The options for rendering single-domain fragments
effective in human therapy described above are crucial
in view of the fact that an increasing number of binders
specific for viruses have been isolated, characterized,
and successfully used in vitro and in animal models. For
example, an effective diagnostic assay based on llama
single-domains for identifying independently four differ-
ent variants of the Marburg virus was delivered in three
working weeks [64]. In this case, the availability of a
semi-synthetic library enabled the reduction of the time
necessary for the selection procedure, providing the evi-
d e n c et h a tr e l i a b l ed i a g n o s t i ci m m u n o a s s a y sb a s e do n
recombinant antibodies can be optimized during the
initial phase of an infective outbreak.
VHHs selected using the group A rotavirus-conserved
VP6 inner capsid protein are yet another example of
efficacy of antibody fragments in neutralizing the virus
and in protecting mice from diarrhea [65,66], where
conventional antibodies had a modest effect. Using a
strategy similar to that used for bacterial pathogens,
VHHs raised against rotavirus were expressed on the
surface of lactobacilli and orally administrated in a
mouse model [67,68]. Severity and duration of the dis-
ease were significantly shortened as a consequence of a
decrease in the viral load. An increase in the variety and
availability of expression cassettes for the secretion or
surface display of VHH antibodies should boost this
approach for the protection from virus and bacteria
infections [68].
Furthermore, VHHs and NAR Vs resulted effective in
detecting poliovirus and inhibiting its replication in vitro
[69,70], in binding vaccinia virus [71], and in preventing
the assembly and secretion of hepatitis B virions in cel-
lular models by the expression of engineered NAR V
and VHH fragments directed against the cellular endo-
plasmic reticulum [72-74].
The inhibition of viral secretion using conventional
antibodies has not been attempted in mammals because
of the technical complexity, but it is becoming feasible
using VHHs expressed as intrabodies. They can inhibit
the multimerization of the HIV-1 Rev protein by
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plasm, and impairing the HIV-1 replication [75]. The
cell uptake of the same virus is impaired by the small
drug AMD3100 that acts as an antagonist for the CD4-
activated co-entry receptorC X C R 4 .C o n v e n t i o n a la n t i -
bodies with the same function had previously been
selected with the aim of isolating receptor antagonists
with longer half-life than AMD3100, but they did not
block sufficiently the virus-receptor recognition. As an
alternative, anti-CXCR4 VHHs have been selected by
competitive elution with the natural binder CXCL12
and successively proved to compete with AMD3100.
Such VHHs behave as competitive antagonists and
potently inhibit the virus uptake [76]. The strategy
a i m e da ti n h i b i t i n gt h eH I V - 1i n f e c t i o nu s i n gV H H s
that recognize envelope proteins and neutralize the vir-
ions by competing with the main cellular receptor CD4
[77-79] is conceptually similar. Finally, nanobodies have
been also used to bind intracellularly the multifunctional
Mf1 domain of the IRF-1 tumor suppressor with the
idea of regulating this viral infection-stimulated regula-
tive protein [80].
Single-domain antibodies were also successfully used
for preparing piezoimmunosensors for the detection of
HIV-1 virions [81]. The possibility of displaying at high
density and controlling the orientation of these binders
o nt h es e n s o rs u r f a c e ss t r o n g l yi n c r e a s e st h em e t h o d
sensitivity.
Finally, the engineering of single-domain antibodies
into multivalent anti-viral molecules have been proved
to increase the neutralizing action against and to reduce
the infectivity of Synctyal, Rabies and influenza viruses
[82,83]. The simultaneous targeting of different epitopes
of the same virus seems a promising alternative to
increased avidity provided by multivalent display of the
same antibody [83].
Toxin identification and detoxification
The use of single-domain antibodies for toxin identifica-
tion and neutralization has increased exponentially in
the last two years. Two are the main reasons for the
success, namely the possibility to use pre-immune
l i b r a r i e sa n dt h eo p p o r t u n i t yt oh a v eas c a f f o l ds t r u c t u -
rally very stable, but extremely suitable for engineering
application-specific modification.
VHH stability is crucial when harsh processing condi-
tions, such as elevated temperatures, high detergent and
reducing agent concentrations, or denaturing conditions,
are used [51,84-86]. Specifically, toxic prolamins can be
effectively extracted for quantification only in the pre-
sence of a solvent containing ethanol, 2-mercaptoetha-
nol and guanidinium chloride. Conventional antibodies
do not withstand these denaturing conditions and,
therefore, are not available for immunological test.
On the contrary, it was possible to select solvent-com-
patible VHHs with increased stability due to an intro-
duction of extra disulfide bonds that constrained the
CDR3 flexibility [84]. N-glycosylation is another para-
meter that allows the antibody stability tuning and can
improve the antibody effectiveness in vivo. Similarly to
what has been observed in the case of anti-virus single-
domain antibodies, N-glycosylation increased the neu-
tralizing capacity of VHHs against the E. coli heat-labile
toxin in a cell model. Such an effect was attributed to
the larger mass of the antibody that blocks simulta-
neously more than one of the five receptor-binding sites
present on each toxin molecule [63].
Parallel panning of one-pot libraries yielded single
domain antibodies in both VHH and NAR V format
specific for ricin, cholera toxin, and staphylococcal
enterotoxin B [71,87,88]. These studies demonstrated
that pre-immune libraries can be used for rapid genera-
tion of antibodies against a large number of harmful
antigens and that the single-domain antibody stability is
beneficial for increasing their shelf life in diagnostic
applications. Furthermore, the troublesome low sensitiv-
ity of single domain antibodies in immunological tests
due to their monovalency could be overcome by using
phage-displayed and not purified antibodies. This
method allows the signal amplification by detecting sev-
eral copies of phage-coating proteins in every single
antibody-toxin binding event [89]. Although conven-
tional IgGs are used preferentially for capturing toxins
in microflow cytometry for multiplexed detection [90]
and in the preparation of metal nanoparticle resistors
for cholera toxin detection [91], single-domain antibo-
dies seem suitable for similar applications [92].
A very interesting application in which single-domain
cannot be substituted by conventional antibodies has
been recently reported [93]. Salmonella SpvB toxin is
secreted directly from the bacteria into the host cell
cytoplasm and, consequently, is not accessible for extra-
cellular antibodies. However, VHHs raised against the
toxin can be expressed and maintain their functionality
and specificity as intrabodies. They block the toxin at a
molar ratio of 1:1 and prevent its pathological conse-
quences at cellular level.
VHHs outperformed conventional antibodies also
when used for the preparation of bivalent and bispecific
constructs used for the in vivo neutralization of the
AahI’/AahII scorpion toxins [94-96]. Multivalency
induced by VHH polymerization [97-99] was exploited
also to increase the neutralizing capacity of antibodies
against the E. coli verotoxin 1 [100], alpha-cobrotoxin
[101], and C. difficile toxin A [102], whereas the reduced
production costs and the high density at which VHH
can be coupled to resin substrates made feasible the
preparation of hemofiltration columns for removing
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staphylococcal-induced sepsis [103,104]. Also an uncon-
ventional mouse VH resulting from an incomplete scFv
antibody has been isolated and characterized because of
its anti-toxin potentialities. In particular, it appeared to
be a functional anti-idiotypic antibody for the HM-1
killer toxin with a higher affinity than scFv antibodies
recovered from the same library for the neutralizing
monoclonal antibody [105].
Toxins such as ricin and botulinum neurotoxin are
classified as bioweapons and have been the object of a
particular attention. In a project aimed at isolating anti-
ricin antibodies, the panning protocol was first opti-
mized using the toxin immobilized on the surface of
microspheres [106]. The isolated VHHs were as effective
as conventional monoclonal antibodies in blocking the
ricin biological activity [107], but were superior in terms
of specificity [108].
The majority of the publications on the toxin topic
concerns the Clostridium botulinum neurotoxin (BoNT)
because it causes frequently fatal disease and there is no
drug able to reverse the symptoms once the toxin has
entered the neuron. The interest in developing single-
domain antibodies against BoNT is primarily motivated
by the stability of these molecules even when they are
expressed in the cytoplasm as intrabodies, facilitating
not only diagnostic [109-111], but also therapeutic
applications. Flow cytometry sorting of pre-immune,
yeast displayed antibodies in VHH format allowed the
isolation of anti-BoNT single-domains against the toxin
light chain that inhibited the toxin protease activity in
vitro and had structural features compatible for their
production in the host cell cytoplasm [85]. Single-
domain antibodies that inhibit the toxin protease activity
by occupying the enzymatic cleft were also recovered
from a mixed VH/VHH library [35], whereas VHHs iso-
lated from an immune library retained their toxin inhi-
bitory properties also when expressed in mammalian
neuronal cell cytosol [112].
Hapten targeting
Small molecules are not expected to be targeted effi-
ciently by single-domain antibodies since they posses a
limited number of conformational epitopes suitable for
recognition by protruding single-domain paratopes.
Nevertheless, there are several examples showing that
VHHs can be exploited for detecting haptens as differ-
ent as herbicides, caffeine, mycotoxins, trinitrotoluene,
steroids and therapeutic drugs [113-120] for this anti-
body class can interact with its targets adopting differ-
ent binding patterns [121]. For instance, the CDR1
loop provides a strong interaction for the azo-dye
Reactive Red 6 [122], CDR2 and a framework residue
contribute to the binding of Reactive Red 1 [123],
whereas a non-conventional, substrate-dependent
dimerization mechanism is involved in the binding of
caffeine and its metabolites [124]. The stability of sin-
gle-domain antibodies expressed in the cytoplasm has
been used to induce their cellular accumulation as an
effective tool for neutralizing the mycotoxin 15-acetyl-
deoxynivaleol in vivo [119].
Reagents for immunodetection, purification and
bioseparation
As an affinity-based technique, immunopurification pre-
sents some theoretical advantages over chromatographic
methods based on chemical and physical properties. It
can simplify complex multi-step procedures to a single
step protocol, reducing production costs and time. Con-
sequently, it can improve yields and limit potential pro-
duct degradation. Nevertheless, immunopurification
performed with conventional antibodies often requests
extreme elution conditions that can damage the purified
product. The advantages offered by single-domain anti-
body fragments in immunochromatography have been
demonstrated for the first time by Verheesen et al.
[125]. Their monomeric nature facilitated the elution of
the target protein, whereas their physical stability and
effective refolding allowed the regeneration of the col-
umn under harsh cleaning conditions for more than
2000 times. Mild elution conditions are necessary to
preserve product structure and activity. From this per-
spective, panning VHH libraries has resulted as being an
optimal solution since binders can be selected not only
based on their specificity, but also on their elution
features. In this way, unstab l ep r o t e i n ss u c ha ss e r u m
factor VIII and alpha-1 antitrypsin have been immuno-
purified successfully using VHH antibodies for their
capture and elution at neutral pH [126,127]. In a com-
parative assay with longer antibody constructs and com-
plete IgGs, affinity columns prepared with VHHs
enabled higher yields, probably because of the higher
density at which they are bound to the matrix [128].
Such VHH-based affinity columns have found their
applications for both purifying specific components
from heterogeneous material [103,129-131] and for
depleting very abundant proteins from samples in which
it is necessary to detect the variation of scarcely repre-
sented polypeptides. It is the case of the platforms
developed for the removal of IgG and human serum
albumin from plasma before processing the samples in
proteomic assays [132] and of the nanotrap for the puri-
fication of GFP-fused proteins from cell homogenates
[133,134]. VHH-based affinity chromatography resulted
also as very effective in removing contaminants such as
DNA and virus particles [135]. At the same time, VHHs
specific for adeno-associated viruses allowed for the sim-
plification of the purification protocol of these
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bling of the final yields [136,137]. Beside the published
reports and filed patent applications, a further indication
of the single-domain antibody reliability as reagents for
immunopurification can be inferred by the list of VHH-
based affinity resins developed by biotech companies
[138,139].
The small dimension (15 KDa, 4 × 2.5 × 3 nm) of sin-
gle-domain antibodies and the possibility to produce
them as recombinant proteins fused to suitable tags
make them inexpensive binders that can be easily
oriented at high density on capture surfaces such as
chips and biosensors or adapted to a large variety of
applications such as purification, imaging, immunomi-
celle and liposome preparation, or immobilization on
nanoparticle resistors for the detection of cancer mar-
kers and cholera toxin [81,92,128,140-146]. A promising
utilization strategy considers the VHH labeling via the
6xHis tag with metastable (99m) technetium for applica-
tion in single-photon emission computed tomography
(SPECT), a noninvasive monitoring technique for obser-
ving the tumor response to therapy [147-152], but nano-
bodies have been effectively labeled also with (68)Ga for
immuno-positron emission tomography (PET) [153]. In
both cases, their elevated tissue penetration and rapid
clearance allow for optimal high-contrast, specific locali-
zation in vivo in a time significantly shorter than that
enabled by using conventional IgGs [145,154,155].
Finally, the use of single-domain antibodies double-
tagged with gadolinium and near-infrared dye Cy5.5
allowed the simultaneous optical and magnetic reso-
nance imaging of brain tumor vessels [156].
Single-domain antibody fragments as crystallography
chaperones and tools for studying protein aggregation
and activity regulation
The possibility of using antibodies to stabilize the con-
formation of proteins that undergo crystallization trials
has been recognized since long time [157-159]. Never-
theless, conventional antibodies and their fragments
have limitations due to their bulky mass (IgG and Fab
fragment) or low stability (scFv) and, therefore, other
molecules have been proposed, such as affibodies, fibro-
nectin, and DARPins [160-162]. Single-domain antibo-
dies seem a logical alternative since they can be
produced inexpensively in short time, have a strong
binding capacity, reduced mass, demonstrated capacity
of providing “induced fit” to the antigen-antibody com-
plex, and they improve crystal packing and X-ray phas-
ing [163-165]. Although VHHs are amenable for simple
site-specific incorporation of SeMet into their scaffolds,
the fact that co-crystallizing with a single-domain anti-
body improves the complementary anomalous disper-
sion data acquisition and gives an ideal template for
molecular replacement represents a substantial advan-
tage for structure resolution [163]. Furthermore, VHHs
are very flexible in terms of interface shapes [121-124]
and, therefore, can adapt to a large variety of epitopes
and block intrinsically flexible regions of their antigens
[166]. VHHs have also been added directly to the solu-
bilized membrane fraction for binding to and stabilizing
the nitric oxide reductase membrane target protein
[167] during the purification that resulted in the recov-
ery of the antigen-antibody complex. No condition giv-
ing rise to diffracting crystals were found with the
enzyme alone, but crystals were obtained in the pre-
sence of the VHHs. It has also been demonstrated that
VHHs and their corresponding antigens can be co-
expressed recombinantly in the same host and co-puri-
fied using tags fused to the antibody sequence, simplify-
ing the protocol for producing antigen-antibody
complexes [140].
The VHH-dependent approaches led to the resolution
of several structures in the last few years [79,167-171].
VHHs seem to favor the formation of crystals of several
different forms and to accelerate in a dramatic way the
crystallization of recalcitrant protein complexes
[168-170]. In the case of the KREPA6 editosome protein
in combination with the Nb5 and Nb15 VHHs, all crys-
tal contacts are obtained by the single-domain co-cha-
perones [170], while the role of VHHs is mainly to keep
the flexible loop connecting the N1 and N2 domains of
GspD in a fixed conformation [168] and to form stabi-
lizing layers between layers of EpsI:EpsJ heterodimers
[169]. Furthermore, although CDR3 is usually the major
component involved in the antigen binding and crystal
chaperoning [172], a feature deriving probably from its
structural flexibility [79], in some cases CDR2 and even
framework 3 can become pivotal chaperoning elements
[170].
I nt h ec a s eo fas t u d yo ft h eGp r o t e i nc o u p l e db2
adrenoreceptor, the VHH characteristics were useful at
different levels. Whereas the crystallization of the inac-
tive state of different members belonging to such recep-
tor class has been achieved, the efforts to obtain a
crystal of the receptor active state were frustrated due
to receptor instability in the absence of G proteins. On
the other hand, the receptor-G protein complex is
unstable in the presence of the detergent necessary for
the receptor stabilization. Therefore, suitable agonists
were necessary for this aim. A high-affinity VHH agonist
of the G protein was successfully identified by panning,
its binding to the receptor was stable, maintained it in
its active form during the crystallization trial functioning
as a substrate agonist, and allowed the structure resolu-
tion operating as a crystallization chaperone [171].
VHHs also proved as being particularly useful for
studying the intermediates of aggregation-prone
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and of the amyloidogenic fragments [174]. Single
domain antibodies of different origin enabled the eluci-
dation of the variety of morphologically distinct Ab
aggregates, blocking their polymerization development
into non-toxic intermediates, and the clarification of the
plausible mechanism of amyloidogenic protein self-asso-
ciation [175-180]. Specifically, domain swapping appears
as a plausible self-association mechanism for amyloido-
genic b2-microglobulin. Protein dimers undergoing
swapping unmask amyloidogenic sequences that fold
into two-stranded antiparallel b-sheet. Self-association of
the sheet b-strands can provide the elongation mechan-
ism by which large intermolecular b-sheets are built
[179]. The first X-ray crystallographic structure of the
complete Ab18-41 fragment has been obtained by an
innovative approach that may be of general interest for
the study of tricky short peptides. The sequence corre-
sponding to the fragment has been cloned inside the
CDR3 of an IgNAR V and the chimeric protein
expressed [180]. In such a way, amyloidogenic oligomer-
ization was allowed through the direct contact of the
exposed Ab fragments, but its uncontrolled development
prevented by the formation of an IgNAR cage. Crystallo-
graphic data confirmed the formation of an Ab frag-
ment-mediated tight tetramer in which the fine
molecular mechanisms of the interaction could be
observed and described.
The structures inferred from crystallographic datasets
were also useful for the understanding of the mechan-
ism by which a nanobody constrained the dehydrofolate
reductase enzyme in its occluded form by binding it in a
region adjacent to the active site. Such allosteric control
of the enzyme activity raised hyperbolic inhibition
kinetics and induced a conformational rearrangement of
the whole enzyme structure [181]. Structural data were
also necessary to explain the allosteric inhibition
mechanism of the botulinum neurotoxin induced by
another VHH [85]. In this case, it was possible to recog-
nize that the antibody epitope corresponded to the a-
exosite of the neurotoxin. This information has practical
potentials since it identifies a target for the development
of inhibitory small-molecule drugs.
Sometimes, the VHH-dependent allosteric enzyme
modulation becomes extremely complex as illustrated
by the case of the interaction between single-domains
and the nucleoside hydrolase from Trypanosoma vivax
[182]. The same antibody inhibited the catalytic path-
way, but increased the product release rate and showed
inhibitory or simulating behavior according to the sub-
strate affinity for the enzyme. Another example of a
complex modulation has been provided by the anti-
human protein kinase C for which two sets of VHHs
were isolated by panning immune libraries. All the five
isolated VHHs were specific exclusively for a single iso-
zyme (PKCε), and surprisingly, whereas three of them
increased the kinase activity in a concentration-depen-
dent manner, the remaining two inhibited the isozyme
[ 1 8 3 ] .T a k e nt o g e t h e r ,t h e s ed a t ai n d i c a t et h a tV H H s
possess not solely of a large array of paratope surfaces
but that, beside their known capacity to block the
enzyme active sites [60,184], they have alternative bind-
ing mechanisms involving different structural regions
that are suitable for tuning their antigen-binding
activity.
Technical considerations-Conclusions
The number of reports dealing with single-domain anti-
body applications in different fields clearly indicates that
this class of immunoreagents represents an important
tool for research as well as biotechnological uses
(Table 1). Furthermore, the described examples show
that single-domain antibodies are complementary rather
than alternative with respect to conventional antibodies
in the sense that perform functions not possible to
accomplish with IgGs.
However, there are several technical issues that still
need to be defined in a systematic way, at the recombi-
nant antibody panning level as well as at the level of
binder production strategies. For instance, the praxis
indicates that one-pot libraries can deliver highly affine
and specific antibodies [29,85,113,185-187], although
somatic maturation was considered essential to obtain
reliable binders. Moreover, it has been emphasized that
non-immune library dimensions and display system
were crucial for obtaining valid recombinant antibodies,
but E. coli, yeast and ribosome display, even though suc-
cessful at simplifying the panning and screening steps by
means of flow-cytometric clone separation [188-191],
did not perform better than small phage display libraries
and recently even minimal libraries have proved to be
potent means of selecting lead antibodies [192]. For a
long time, an elevated affinity has been considered an
absolute necessity, but now we know that it is important
Table 1 Available literature relative to the different
biotechnological applications analyzed in the review
Field of Application References
Bacteria and Phages 20,38-41,43-50
Fungi and Protozoans 51-58
Viruses 60-83
Toxins 35,63,71,84-89,92-112
Haptens 113-124
Immunodetection, Immunopurification,
Bioseparation
81,92,125-156
Crystallography, Aggregates, Enzyme
regulation
53,60,79,85,140,163-
183,200
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with appropriate tumor penetration in vivo [193,194].
Finally, several applications in chromatography, biose-
paration, crystallography, or therapy need large amounts
of recombinant antibodies and their fusion derivates,
but their production technology has not improved sig-
nificantly, although innovations concerning their expres-
sion in both bacterial periplasm [195,196] and in
eukaryotic systems have been introduced [65,197]. How-
ever, a breakthrough seems to have arrived now with
the advent of a technology enabling the cytolasmic accu-
mulation of disulfide bond-dependent proteins. This
approach aims at inducing the disulfide bond formation
by co-expressing a sulfhydryl oxidase instead of disrupt-
ing the reducing pathways in the cytosol [198,199] and
resulted in yields of VHH-fusion constructs in the range
of several tens of mg/L culture [200].
Given the excellent qualitative performance of single-
domain antibodies and their advantages in terms of
structural features, stability, and production costs, a
question remains to be answered as to why it has taken
almost twenty years for them to become largely popular
in the scientific community. Probably two reasons are
the main responsible for this slow technology acknowl-
edgment. The pretty restrictive intellectual property pol-
icy introduced by the inventor institutions with the
“Hamers patents” that first defined the field has been
extremely successful in boosting the spin-off companies
funded to exploit the discovery, but it has probably pre-
vented other actors from participating in the develop-
ment. The second reason concerns the fact that for a
long time there was only a minimal availability of those
application-friendly tools for research and diagnostics
that are necessary for making new technologies appeal-
ing to non-specialist researchers [201]. With the original
patents expiring in the next few years and the recent
accessibility of new libraries, protocols, and vectors sui-
table for different immunoapplications, we expect an
increase of the interest of both research and industry for
this class of recombinant antibodies in the near future.
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